ClinicalTrials.gg
Enrolling by invitationNCT07503769CHU-VAUpdated Mar 31, 2026

CHU Dual-Energy Ablation in Ventricular Arrhythmia

An interventional study of ablation in Premature Ventricular Contractions and Ventricular Tachycardia, sponsored by Shanghai MicroPort EP MedTech Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Shanghai MicroPort EP MedTech Co., Ltd. (formerly part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as enrolling by invitation.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the safety of the dual-energy ablation catheter manufactured by Shanghai MicroPort EP Medical Technology Co., Ltd. in the treatment of tachyarrhythmias.

02

Conditions studied

  • Premature Ventricular Contractions
  • Ventricular Tachycardia

Keywords

  • PVCs
  • VT
03

In context

Ventricular Premature Complexes

102 studies on the registry are indexed under Ventricular Premature Complexes; 32 are open to participants now.

This study's planned enrollment of 10 is below the median of 84 across 58 interventional studies indexed under Ventricular Premature Complexes.

Browse Ventricular Premature Complexes studies →

Lead sponsor

Shanghai MicroPort EP MedTech Co., Ltd. is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

First submitted after Shanghai MicroPort EP MedTech Co., Ltd. left MicroPort Scientific Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient age ≥ 18 years and ≤ 75 years;
  • Clinically diagnosed with tachyarrhythmia, specifically idiopathic ventricular arrhythmia;
  • Recurrent disease with obvious symptoms prior to enrollment;
  • Failure to respond to or intolerance of at least one antiarrhythmic drug;
  • Fully understand the treatment plan, voluntarily sign the form, and agree to undergo the examinations, procedures and follow-up as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  • (LVEF) ≤ 40%
  • History of ventricular flutter or ventricular fibrillation
  • Diagnosis of long syndrome or arrhythmogenic cardiomyopathy
  • Presence of structural heart disease or organic heart disease, including hypertrophic cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy, rheumatic heart disease, and congenital heart disease
  • Previous atrial septal repair or atrial myxoma
  • Carrying an active implantable device in the body (e.g., cardiac pacemaker, ICD, etc.)
  • functional class Ⅲ-Ⅳ
  • Patients with documented cerebrovascular disease within the past 6 months (including cerebral hemorrhage, stroke, )
  • Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting, prosthetic valve replacement or repair, atrial or ventricular incision)
  • Patients with acute or severe systemic infection
  • Patients with severe hepatic or renal disease, malignant tumor, or end-stage disease, who, in the investigator's judgment, may interfere with the treatment, evaluation, or compliance of this trial
  • Patients with significant bleeding tendency, hypercoagulable state, or severe hematological disorders
  • Patients who have participated in or are currently participating in other clinical trials within 3 months prior to enrollment
  • Patients with other conditions deemed inappropriate for participation in this trial by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Catheter ablation

    All enrolled subjects will undergo radiofrequency or pulsed ablation for idiopathic ventricular arrhythmias using the investigational catheter.

    Device: ablation

Interventions

  • Deviceablation

    All enrolled subjects will undergo radiofrequency or pulsed ablation for idiopathic ventricular arrhythmias using the investigational catheter.

    Also known as: Pulsed Field Ablation Device and CF-Sensing Pulsed Field Ablation Catheter

06

What researchers measure

Primary outcomes

  1. Success rate of catheter ablation

    The primary efficacy endpoints were to evaluate the acute and 3-month follow-up success rate after ablation

    Time frame: at end of the procedure, 1-month follow-up, 3-month follow-up

Secondary outcomes

  1. Immediate success rate of ablation

    It is defined as the disappearance of the identical outflow tract ventricular arrhythmia that was present pre-ablation, with no inducible sustained identical outflow tract ventricular arrhythmia during 20 minutes of observation following pharmacological and/or electrophysiological stimulation.

    Time frame: immediate ablation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — This trial protocol is available in Chinese only and has not yet been translated into English.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07503769
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Feb 3, 2026
Primary completion
Jul 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Mar 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion